Renaissance Capital logo

HilleVax Priced, Nasdaq: HLVX

Phase 2 biotech developing a novel norovirus vaccine in-licensed from Takeda.

Industry: Health Care

Latest Trade: $1.98 0.00 (0.0%)

First Day Return: +12.3%

Return from IPO: -88.4%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing novel vaccines. Our initial program, HIL-214, is a virus-like particle, or VLP-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year, as well as significant additional economic and social burden. To date, HIL-214 has been studied in nine clinical trials conducted by Takeda and LigoCyte, which collectively generated safety data from more than 4,500 subjects and immunogenicity data from more than 2,200 subjects, including safety and immunogenicity data from more than 800 pediatric subjects. A randomized, placebo-controlled Phase 2b field efficacy trial enrolled 4,712 adult subjects, and HIL-214 was well tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of AGE from norovirus infection. In September 2021, an open IND was transferred to us from Takeda, under which we plan to initiate a Phase 2b clinical trial in the 2Q22 to evaluate the safety, immunogenicity, and efficacy of HIL-214 in infants. We expect to report interim safety data from this trial for the first 200 subjects in the second half of 2022, interim immunogenicity data for the first 200 subjects in the 1H23, and top-line data in the 2H23. We believe HIL-214 has the potential to be the first ever vaccine approved for norovirus-related illness.
more less
IPO Data
IPO File Date 04/06/2022
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 11.8
Deal Size ($mm) $200
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/28/2022
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 11.8
Deal Size ($mm) $200
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
J.P. Morgan
Leerink Partners
more
Company Data
Headquarters Boston, MA, United States
Founded 2019
Employees at IPO 31
Website www.hillevax.com

HilleVax (HLVX) Performance